Dibekacin

(2R,3R,4S,5S,6R)-4-Amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-yl]oxy-2-hydroxy-cyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol Struktur
34493-98-6
CAS-Nr.
34493-98-6
Bezeichnung:
Dibekacin
Englisch Name:
(2R,3R,4S,5S,6R)-4-Amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-yl]oxy-2-hydroxy-cyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol
Synonyma:
DIBEKACIN;ibekacin;Aids070753;Brn 1441606;Aids-070753;4)]-2-deoxy-;Dibekacin USP/EP/BP;4'-Dideoxykanamycin B;Dibekacin(Dideoxykanamycin B);D-StreptaMine,O-3-aMino-3-deoxy-a-D-glucopyranosyl-(1®
CBNumber:
CB02130442
Summenformel:
C18H37N5O8
Molgewicht:
451.52
MOL-Datei:
34493-98-6.mol

Dibekacin Eigenschaften

alpha 
D20 +132° (c = 0.65)
Siedepunkt:
559.28°C (rough estimate)
Dichte
1.3132 (rough estimate)
Brechungsindex
1.7600 (estimate)
pka
13.07±0.70(Predicted)
CAS Datenbank
34493-98-6

Sicherheit

Toxizität LD50 in mice (mg/kg): 61.0-68.0 i.v., 373.0-380.0 i.m. (Komiya)

Dibekacin Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Dibekacin was synthesized in 1967 by Umezawa et al. by the removal of the 3 - and 4 -hydroxyl groups of kanamycin B. Studies by the same workers on the mechanisms of bacterial resistance to kanamycin-group antibiotics preceded the discovery. Dibekacin shows excellent activity, as expected, against a variety of bacteria, including kanamycin-resistant strains. It shows higher activity than kanamycin against Pseudomonas aeruginosa, Proteus, and other pathogens.

Verwenden

Dideoxykanamycin B is an antibacterial compound.

Definition

ChEBI: A kanamycin that is kanamycin B lacking the 3- and 4-hydroxy groups on the 2,6-diaminosugar ring.

Antimicrobial activity

3′,4′-Dideoxy kanamycin B. A semisynthetic aminoglycoside closely related to the natural compound tobramycin (3′-deoxy kanamycin B). Supplied as the sulfate.
It is active against staphylococci including methicillinresistant strains, a wide range of enterobacteria, Acinetobacter and Pseudomonas spp. It is also active against M. tuberculosis and the M. avium complex (MICs 4–16 mg/L). It exhibits the usual aminoglycoside properties of bactericidal activity at concentrations close to the MIC and bactericidal synergy with selected β-lactam antibiotics.
Absence of hydroxyl groups present in the parent kanamycin B renders dibekacin resistant to phosphorylation by APH(3′). It is also resistant to some forms of ANT(4′). However, the type of this enzyme, ANT(4′), found in some Gram-positive organisms modifies dibekacin at the 2″-hydroxyl group; nevertheless dibekacin has much greater activity than tobramycin against organisms that produce the enzyme.
A 1 mg/kg intravenous bolus dose achieves a peak plasma concentration of around 5 mg/L. The plasma half-life is 2.3 h. Protein binding is 3–12%. It is eliminated principally by the renal route, 75–80% of the dose appearing in the urine in the first 24 h. Elimination is inversely related to renal function. In patients maintained on chronic hemodialysis, the half-life rises to 54 h between dialyses and falls to 6–7 h on dialysis.
Toxic effects are those typical of aminoglycosides with a frequency similar to or less than those of gentamicin.
It is used for severe infections caused by susceptible microorganisms, especially those resistant to established aminoglycosides, but availability is limited.

Sicherheitsprofil

Poison by intraperitoneal, subcutaneous, intramuscular, and intravenous routes. Moderately toxic by ingestion. Experimental teratogenic and reproductive effects. An antibacterial agent. When heated to decomposition it emits toxic fumes of NOx.

Dibekacin Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


Dibekacin Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 16)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
CONIER CHEM AND PHARMA LIMITED

sales@conier.com China 49906 58
TargetMol Chemicals Inc.
+1-781-999-5354; +1-00000000000
marketing@targetmol.com United States 32431 58
Shaanxi Dideu Medichem Co. Ltd
+86-29-81139210 +86-17392587031
1059@dideu.com China 9984 58
HANGZHOU LEAP CHEM CO., LTD.
+86-571-87711850 +86-15355479329
market18@leapchem.com China 43303 58
XIAMEN AMITY INDUSTRY AND TRADE CO., LTD.
+8618950047208
ellena@amitychem.com China 43392 58
Chongqing Qiantai Pharma Co., Ltd.
17864179792
richardchan@bright-gene.com China 95 58
T&W GROUP 021-61551611 13296011611
contact@trustwe.com China 9884 58
Beijing HuaMeiHuLiBiological Chemical 010-56205725
waley188@sohu.com China 12323 58
Quality Control Solutions Ltd. 0755-66853366 13670046396
orders@qcsrm.com China 18188 56
Chizhou Kailong Import and Export Trade Co., Ltd.
xg01_gj@163.com China 9413 50

34493-98-6(Dibekacin)Verwandte Suche:


  • (2R,3R,4S,5S,6R)-4-Amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-yl]oxy-2-hydroxy-cyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol
  • 6-O-(3-Amino-3-deoxy-α-D-glucopyranosyl)-4-O-(2,6-diamino-2,3,4,6-tetradeoxy-α-D-erythro-hexopyranosyl)-2-deoxy-D-streptamine
  • Aids070753
  • Aids-070753
  • Brn 1441606
  • D-Streptamine, o-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-o-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-D-erythro-hexopyranosyl)-(1-4)-2-deoxy-
  • O-3-AMino-3-deoxy-α-D-glucopyranosyl-(1→6)-O-[2,6-diaMino-2,3,4,6-tetradeoxy-α-D-erythro-hexopyranosyl-(1→4)]-2-deoxy-D-streptaMine
  • 4)]-2-deoxy-
  • 6)-O-[2,6-diaMino-2,3,4,6-tetradeoxy-a-D-erythro-hexopyranosyl-(1®
  • D-StreptaMine,O-3-aMino-3-deoxy-a-D-glucopyranosyl-(1®
  • (2S,3R,4S,5S,6R)-4-amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol
  • Dibekacin(Dideoxykanamycin B)
  • (2S,3R,4S,5S,6R)-4-amino-2-(((1S,2S,3R,4S,6R)-4,6-diamino-3-(((2R,3R,6S)-3-amino-6-(aminomethyl)tetrahydro-2H-pyran-2-yl)oxy)-2-hydroxycyclohexyl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,5-diol
  • Dibekacin USP/EP/BP
  • 4'-Dideoxykanamycin B
  • ibekacin
  • D-Streptamine, O-3-amino-3-deoxy-α-D-glucopyranosyl-(1→6)-O-[2,6-diamino-2,3,4,6-tetradeoxy-α-D-erythro-hexopyranosyl-(1→4)]-2-deoxy-
  • DIBEKACIN
  • 34493-98-6
  • 4493-98-6
Copyright 2019 © ChemicalBook. All rights reserved